Comamonas species are saprophytes, thought to be rarely associated with clinical infections.We report five cases of Comamonas species associated with gastrointestinal (GI) manifestations isolated over a period of 2 years.All these patients had underlying GI pathologies like malignancy or inflammatory bowel disease.This report tends to introspect on the clinical significance of such rare pathogens in stool samples and emphasize its possible role in causing GI infections.

Patients with inflammatory bowel disease (IBD) are at an increased risk of infection due to factors like use of immunosuppressive drugs and poor nutritional status.[1] Immunization is a cost-effective and simple way to protect against several infections. Some of the recommended vaccines in IBD include those against hepatitis B, influenza, varicella, pneumococcus, diphtheria, tetanus, measles, mumps, rubella, and hepatitis A. However, despite the recommendations by various expert groups and societies, the rate of vaccination against infectious diseases is quite low among patients with IBD.[1] [2] Hepatitis A virus (HAV) is an RNA virus that is transmitted through contaminated food and water or direct contact. Infection is common in regions with poor sanitation and hygiene. It is one of the causes of acute viral hepatitis, although the infection is asymptomatic in vast majority of the cases. Vaccines (inactivated as well as live attenuated) are available against HAV and after two doses, they offer more than 95% protection against infection.[3] Yet vaccination rate against hepatitis A is poor in patients with IBD.[1]

Background The outcomes from fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (rCDI) in patients after complete or partial colectomy are not well-defined. Objectives We sought to report our experience with FMT for rCDI in patients who have undergone colectomy. Methods Descriptive analyses of FMT outcomes from 2014 to 2020 were performed in patients who previously had undergone complete or partial colectomy. Results Twenty-nine patients with prior colectomy for inflammatory bowel disease, malignancy, slow-transit constipation refractory to medical therapy, or fulminant CDI underwent FMT for rCDI. Two patients (6.9%) had rCDI within 8 weeks post-FMT. Seven had CDI beyond 8 weeks (median 10 months) with 71% related to antibiotic exposure post-FMT, suggesting a 69% overall success. Conclusion FMT resolves rCDI in most patients after colectomy with subsequent antibiotic exposure predicting CDI after FMT.

publication of the Gastrointestinal Infection Society of India, has been assigned to M/s Jaypee Brothers Medical Publishers, New Delhi, for publishing and distributing the journal worldwide, both in print and electronic media.Every issue of the journal will be hosted online at